Related Experiment Video
Updated: Jan 12, 2026
An In Vivo Method to Study Mouse Blood-Testis Barrier Integrity
Published on: December 2, 2018
Atorvastatin improves spermatogenesis in murine and in vitro human chronic orchitis models through restoring
Linzi Ma1,2, Jiyu Chen2, Qi Li2
1Center for Reproductive Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Abstract:
Chronic orchitis, which stems from autoimmune responses and infections, significantly impairs the testicular niche and affects male fertility. However, there is a lack of effective therapeutic drugs. In this study, we aimed to explore whether atorvastatin can be used for the treatment of chronic orchitis and the underlying mechanism based on our previous findings and detection using the database. We utilized mouse models of chronic orchitis induced by both autoimmune and infectious causes to demonstrate that atorvastatin can markedly improve spermatogenesis and fertility. Mechanism studies through single-cell transcriptomic analysis, target gene knockdown, quantitative proteomics, and small molecule interference revealed that atorvastatin suppressed the Rac1/AP1/MMPs pathway via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) in Sertoli cells, thereby restoring the blood-testis barrier (BTB) and spermatogenesis. More importantly, atorvastatin also re-established the expression of BTB-associated proteins and increased the germ cell numbers in cultured human testis tissues. Collectively, our study reveals the essential impact of atorvastatin in improving spermatogenesis in murine and human chronic orchitis models through restoring BTB and suggests that atorvastatin as a promising agent for the clinical treatment of chronic orchitis.
Insights
Atorvastatin effectively treats chronic orchitis by restoring the blood-testis barrier (BTB) and improving sperm production in mice and humans. This study highlights its potential as a therapeutic drug for male infertility.
Area of Science:
- Reproductive Biology
- Pharmacology
- Immunology
Background:
- Chronic orchitis, caused by autoimmune issues or infections, severely impacts male fertility.
- Current therapeutic options for chronic orchitis are limited.
- Understanding the mechanisms behind testicular damage is crucial for developing new treatments.
Purpose of the Study:
- To investigate the therapeutic potential of atorvastatin for chronic orchitis.
- To elucidate the underlying molecular mechanisms of atorvastatin's action in restoring testicular function.
- To evaluate atorvastatin's efficacy in both preclinical models and human tissue.
Main Methods:
- Induction of chronic orchitis in mouse models (autoimmune and infectious).
- Administration of atorvastatin and assessment of spermatogenesis and fertility.
- Single-cell transcriptomic analysis, target gene knockdown, and quantitative proteomics.
- In vitro studies using cultured human testis tissues.
Main Results:
- Atorvastatin significantly improved spermatogenesis and fertility in mouse models.
- Mechanism studies revealed atorvastatin suppresses the Rac1/AP1/MMPs pathway by inhibiting HMGCR in Sertoli cells.
- Atorvastatin restored the blood-testis barrier (BTB) integrity and increased germ cell numbers in human testis tissues.
Conclusions:
- Atorvastatin effectively restores the BTB and improves spermatogenesis in experimental chronic orchitis.
- The drug acts by inhibiting the HMGCR/Rac1/AP1/MMPs pathway in Sertoli cells.
- Atorvastatin shows promise as a novel therapeutic agent for clinical treatment of chronic orchitis and associated male infertility.
Related Concept Videos
01:41Spermatogenesis
01:23Infertility in Males